Details:
The financing will advance company’s proprietary self-adjuvanting and multi-antigen vaccine technology platform and to accelerate its vaccine pipeline, including LBT-SA7 (formerly IBT-V02), to prevent reinfections caused by the bacterial pathogen Staphylococcus aureus.
Lead Product(s): LBT-SA7
Therapeutic Area: Infections and Infectious Diseases Product Name: LBT-SA7
Highest Development Status: IND Enabling Product Type: Vaccine
Partner/Sponsor/Collaborator: Adjuvant Capital
Deal Size: $40.0 million Upfront Cash: Undisclosed
Deal Type: Series A Financing February 01, 2024